YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names. Continue Reading
Shares of Oruka Therapeutics ORKA have witnessed a strong rally over the past three months, primarily driven by growing investor confidence in the company's lead asset, ORKA-001, and broader clinical progress. ORKA Price Performance Shares…
Oruka Therapeutics, Inc. MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the trea…
The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biotec…
The VanEck Pharmaceutical ETF (NASDAQ:PPH) offers concentrated exposure to established global drugmakers and higher yields, while the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a diversified, higher-volatility play on smaller…
The National Psoriasis Foundation recognizes August as Psoriasis Awareness Month, an annual initiative aimed at raising awareness, educating the public and supporting efforts to improve the lives of people affected by psoriasis and psoriat…
(RTTNews) - Oruka Therapeutics, Inc. (ORKA), a clinical-stage biotechnology company that develops biologics for the treatment of chronic skin diseases, reported second-quarter 2026 financial results reflecting a wider net loss and provided…
EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 16 data now expected in 4Q 2026 Phase 3 program for ORKA-001 expecte…
Key Points iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total re…
Investors choosing between iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) must weigh the high-growth potential of specialized U.S. biotech against a more stable, dividend-paying global healt…
Key Points State Street Health Care Select Sector SPDR ETF provides a much lower expense ratio of 0.08% compared to the 0.35% for State Street SPDR S&P Biotech ETF. State Street Health Care Select Sector SPDR ETF offers a higher trailing-1…
While State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) offers broad exposure to established healthcare giants at a minimal cost, State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides a more volatile, equal-weighted focus on…
Plus, other significant moves in holdings of Oruka Therapeutics, Enliven Therapeutics, NN, and Alvotech. Continue Reading
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the st…
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics (NASDAQ:ORKA), reported the direct sale of 9,854 shares of Common Stock for proceeds of approximately $687K across June 12 and June 15, 2026, according to the SEC Form 4 f…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Pre-market movers give traders an early read on momentum, sentiment, and potential volatility for the trading day. Price swings before the opening bell t…
Key Points 105,000 Common Stock shares were sold for a transaction value of ~$6.19 million at around $58.97 per share on May 21, 2026. This disposition represented 58.74% of Dambkowski's direct holdings, reducing direct ownership from 178,…
Carl Dambkowski, Director of Oruka Therapeutics(NASDAQ:ORKA), reported the sale of 105,000 shares of Common Stock for a total of approximately $6.19 million on May 21, 2026, according to a SEC Form 4 filing. Transaction summary Metric Valu…
Avidity Partners Management disclosed a buy of 259,700 shares of Enliven Therapeutics(NASDAQ:ELVN) in its May 13, 2026, SEC filing, an estimated $7.19 million transaction based on quarterly average pricing. What happened According to a SEC…
Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 milli…
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million based on quarterly average pricing. What…
Halozyme Therapeutics (HALO) posted stronger-than-expected Q1 results, with revenue beating consensu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Halozyme Therapeutics, Inc. is one of the best cancer stocks to invest in. TheFly reported on April 29 that H.C. Wainwright increased its price objective fo…
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink Partners lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $109 on April 30, reaffirming an Outperf…
Agreement provides exclusive rights for IL-23p19 in psoriatic disease and option for one additional target SAN DIEGO and MENLO PARK, Calif., May 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") and Oruka Ther…
Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibo…
Oruka Therapeutics (ORKA [https://seekingalpha.com/symbol/ORKA]) has announced an upsized public offering [https://seekingalpha.com/pr/20491699-oruka-therapeutics-announces-pricing-of-upsized-700-million-underwritten-public-offering] of 9.…
(RTTNews) - Oruka Therapeutics, Inc. (ORKA), has priced an upsized $700.4 million underwritten public offering, strengthening its balance sheet as the company advances two late-stage dermatology programs designed for ultra-infrequent dosin…
MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory an…
(RTTNews) - Oruka Therapeutics, Inc. (ORKA), a clinical-stage biopharmaceutical company, announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock, to certain…
Oruka Therapeutics Inc. (NASDAQ:ORKA) is one of the 10 Stocks Racking Up Monster Gains. Oruka Therapeutics soared to a new record high on Monday, as investors positioned portfolios following positive results from the clinical study of its…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.01%. June E-mini S&P futures (ESM26) rose +0.14%, and June E-…
The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.01%. June E-mini S&P futures (ESM26) rose +0.14%, and June E-…
The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.30%. June E-mini S&P futures (ESM26) are down -0.14%, and June E-mini Nas…
Check out the companies making the biggest moves in midday trading: Sandisk , Micron — Memory stocks were trading higher after Melius Research highlighted the group and said the artificial intelligence cycle should keep demand high for mem…